Tags

Type your tag names separated by a space and hit enter

Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
J Clin Oncol. 2003 May 01; 21(9):1653-9.JC

Abstract

PURPOSE

Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue. These physical changes can negatively affect health-related quality of life. Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.

METHODS

In a two-site study, 155 men with prostate cancer who were scheduled to receive androgen deprivation therapy for at least 3 months after recruitment were randomly assigned to an intervention group that participated in a resistance exercise program three times per week for 12 weeks (82 men) or to a waiting list control group (73 men). The primary outcomes were fatigue and disease-specific quality of life as assessed by self-reported questionnaires after 12 weeks. Secondary outcomes were muscular fitness and body composition.

RESULTS

Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group. Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group. The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.

CONCLUSION

Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy. This form of exercise can be an important component of supportive care for these patients.

Authors+Show Affiliations

Department of Medical Oncology, Ottawa Regional Cancer Centre-General Site, 503 Smyth Rd, Ottawa, Ontario K1H 1C4, Canada. Roanne.Segal@orcc.on.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12721238

Citation

Segal, Roanne J., et al. "Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 21, no. 9, 2003, pp. 1653-9.
Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21(9):1653-9.
Segal, R. J., Reid, R. D., Courneya, K. S., Malone, S. C., Parliament, M. B., Scott, C. G., Venner, P. M., Quinney, H. A., Jones, L. W., D'Angelo, M. E., & Wells, G. A. (2003). Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 21(9), 1653-9.
Segal RJ, et al. Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2003 May 1;21(9):1653-9. PubMed PMID: 12721238.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. AU - Segal,Roanne J, AU - Reid,Robert D, AU - Courneya,Kerry S, AU - Malone,Shawn C, AU - Parliament,Matthew B, AU - Scott,Chris G, AU - Venner,Peter M, AU - Quinney,H Arthur, AU - Jones,Lee W, AU - D'Angelo,Monika E Slovinec, AU - Wells,George A, PY - 2003/5/2/pubmed PY - 2003/5/21/medline PY - 2003/5/2/entrez SP - 1653 EP - 9 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 21 IS - 9 N2 - PURPOSE: Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue. These physical changes can negatively affect health-related quality of life. Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat. METHODS: In a two-site study, 155 men with prostate cancer who were scheduled to receive androgen deprivation therapy for at least 3 months after recruitment were randomly assigned to an intervention group that participated in a resistance exercise program three times per week for 12 weeks (82 men) or to a waiting list control group (73 men). The primary outcomes were fatigue and disease-specific quality of life as assessed by self-reported questionnaires after 12 weeks. Secondary outcomes were muscular fitness and body composition. RESULTS: Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group. Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group. The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds. CONCLUSION: Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy. This form of exercise can be an important component of supportive care for these patients. SN - 0732-183X UR - https://www.unboundmedicine.com/medline/citation/12721238/Resistance_exercise_in_men_receiving_androgen_deprivation_therapy_for_prostate_cancer_ L2 - https://ascopubs.org/doi/10.1200/JCO.2003.09.534?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -